[2026] CCRP PDF Questions – Perfect Prospect To Go With DumpsMaterials Practice Exam [Q59-Q80]

May 1, 2026 examdumps 0 Comment

Tags: CCRP best vce, CCRP regualer update, CCRP test engine, CCRP valid exam cram pdf, CCRP valid study questions pdf, new CCRP exam pass4sure

4.5/5 - (2 votes)

[2026] CCRP PDF Questions – Perfect Prospect To Go With DumpsMaterials Practice Exam

SOCRA CCRP Pdf Questions – Outstanding Practice To your Exam

SOCRA CCRP Exam Syllabus Topics:

Topic	Details
Topic 1	Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.
Topic 2	Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study’s compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study’s commencement.\|Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.

Topic

Details

Topic 1

Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.

Topic 2

Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study’s compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study’s commencement.|Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.

NEW QUESTION 59
A clinical investigator is developing the assent procedure for the enrollment of children into a new pediatric clinical trial. The ages of the children are described in the IRB/IEC submission. A description of which of the following must also be included in the submission?

The psychological status of the children

The economic status of the children

The physiological status of the children

The pediatrician (primary care provider notification process)

NEW QUESTION 60
In accordance with the ICH E2A Guideline, the sponsor must report an adverse event that is life-threatening, unexpected, and associated with the investigational drug to the regulatory authority as soon as possible but no later than how many calendar days after first knowledge of the event?

1 day

7 days

10 days

15 days

NEW QUESTION 61
An investigator received an updated investigator’s brochure from the sponsor; the update did not include changes related to subject safety. Which of the following parties, if any, is the investigator required to notify?

The IRB/IEC

The Data Safety Monitoring Board (DSMB)

The regulatory authority

No notification is required

NEW QUESTION 62
A research site was invited to participate in an investigational drug study. Which of the following parties is responsible for determining the risk-benefit ratio at the site?

The clinical investigator

The IRB/IEC

The site’s legal counsel

The sponsor

NEW QUESTION 63
What is included in the Statement of Investigator (Form FDA 1572)?

A statement disclosing investigator financial interests

A statement responding to FDA inspection observations

A statement describing preclinical and human safety data

A statement agreeing to comply with FDA regulations

NEW QUESTION 64
Upon completion of a study, the investigator should do which of the following?

As soon as possible, provide the IRB/IEC with a final report that summarizes the trial’s outcome

Ensure that all payments from sponsor have been received

Provide the IRB/IEC a final report, but only if the study has a positive outcome

Compile site data, publish the study results, and submit the publication to the IRB/IEC as the final report

NEW QUESTION 65
In order to meet recruitment goals, a sponsor is adding a new site to a multi-center study. Which of the following documents should the sponsor obtain from a new site prior to starting research at the site?

The site’s SOPs

The delegation of duties log

The site’s accreditation certificate

The IRB/IEC trial approval documentation

NEW QUESTION 66
A pharmaceutical company is developing a biologic study. In accordance with ICH, which of the following items should be included in an investigator’s brochure (IB)?

Lab draw requirements

Results of recent nude mouse study

Dispensing instructions

Schedule of events

NEW QUESTION 67
The sponsor of a multi-institutional clinical trial provided a site with information regarding a newly identified unanticipated adverse event attributed to study drug administration. The site’s investigator has a subject actively receiving this study drug. Which of the following is the site investigator’s responsibility to the subject?

To discontinue the subject’s study drug

To submit this safety update to the regulatory authority

To provide the subject with information regarding the significant new findings

To give the subject’s contact information to the sponsor in order to allow the sponsor to contact the subject

NEW QUESTION 68
In accordance with the CFR, for at least how many years after the completion of a study must the clinical investigator provide the sponsor with relevant changes to financial information?

One year

Two years

Three years

Five years

NEW QUESTION 69
Which of the following should a clinical investigator include in a submission to an IRB/IEC for a Phase IV drug study?

The itemized study budget

The amount of payments and compensation to subjects

The drug development and marketing plan

The investigator’s clinical trial agreement with the sponsor

NEW QUESTION 70
In determining the classification of risk for a study involving a medical device, it is necessary to consider the:

Number of patients to be treated with the device

Cost of device

Investigators’ prior training and experience

Use of the device in the particular study

NEW QUESTION 71
The reviewing IRB/IEC determined that a minimal risk sponsor-investigator study is exempt from IRB/IEC review. How often, if ever, is the sponsor-investigator required to submit a continuing review to the IRB/IEC?

Every year

Every two years

Exactly one time, at study closure

There is no such requirement

NEW QUESTION 72
While reviewing site records during a monitoring visit, a monitor can cite which of the following as a site violation of informed consent regulations?

A subject’s signature is missing on the copy of the summary of the short form consent

A copy of the consent document was not provided to a subject

Only the signatures of the person obtaining consent and the witness appear on the copy of the summary of the short form consent

The sponsor-generated informed consent template is missing required elements

NEW QUESTION 73
In accordance with the Belmont Report, obtaining voluntary informed consent from subjects prior to enrolling them in a clinical trial is an example of which of the following ethical principles?

Do no harm

Respect for persons

Beneficence

Justice

NEW QUESTION 74
In order to adequately monitor a clinical trial, the monitor must be familiar with each of the following, EXCEPT the:

Written information to be provided to the subjects

Requirements for storage of the investigational product

Sponsor’s SOPs

IRB/IEC requirements for reporting to the regulatory authority

NEW QUESTION 75
During an IND study closeout, a monitor discovered remaining investigational product. Which procedures must be followed for disposition?

Sponsor’s procedures

IRB/IEC’s procedures

Regulatory authority’s procedures

Dispensing pharmacy’s procedures

NEW QUESTION 76
An unconscious patient experiencing life-threatening cardiac arrhythmias has been admitted to an emergency room. No FDA-approved treatment is available, and no legal representative is present. The clinical investigator determined that the use of an investigational antiarrhythmic drug is required. In accordance with the CFR, who must certify the investigator’s determination?

A sub-investigator

An independent physician

The sponsor’s study monitor

The sponsor’s medical monitor

NEW QUESTION 77
An investigator is working with a new sponsor to submit a cardiovascular trial to the IRB/IEC. In accordance with the ICH GCP Guidelines, which parties should sign the protocol to confirm agreement that the trial will be conducted as agreed?

The investigator/institution and the sponsor

The investigator/institution and the delegated site staff

The sponsor and the IRB/IEC

The sponsor and the FDA

NEW QUESTION 78
An approved investigational device exemption (IDE) permits a device to be:

Shipped lawfully for the purpose of conducting a clinical study

Sold and marketed for profit

Used on a patient who is not enrolled on a clinical study

Marketed as a humanitarian device

NEW QUESTION 79
An investigator received an updated informed consent form (ICF) from the sponsor for a study closed to enrollment. Subjects are only in long-term follow-up. The change related to frequent radiation imaging at screening, with no change to drug safety profile. Who must the investigator notify first?

Sub-investigators

Participants in long-term follow-up

The IRB/IEC

No notification is required

NEW QUESTION 80
In accordance with the ICH GCP Guideline and the CFR, who is directly responsible for ensuring that an IRB
/IEC will conduct the initial and continuing review of a study?

The sponsor

The monitor

The investigator

The study coordinator